EP0753062A4 - Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs - Google Patents

Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs

Info

Publication number
EP0753062A4
EP0753062A4 EP95905220A EP95905220A EP0753062A4 EP 0753062 A4 EP0753062 A4 EP 0753062A4 EP 95905220 A EP95905220 A EP 95905220A EP 95905220 A EP95905220 A EP 95905220A EP 0753062 A4 EP0753062 A4 EP 0753062A4
Authority
EP
European Patent Office
Prior art keywords
constructs
compound
recombinant retroviruses
packaging sequence
sequence expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95905220A
Other languages
German (de)
French (fr)
Other versions
EP0753062A1 (en
Inventor
Geoffrey P Symonds
Lun-Quan Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gene Shears Pty Ltd
Original Assignee
Gene Shears Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/178,082 external-priority patent/US5712384A/en
Application filed by Gene Shears Pty Ltd filed Critical Gene Shears Pty Ltd
Priority to DK02025406T priority Critical patent/DK1298208T3/en
Priority to EP02025406A priority patent/EP1298208B1/en
Publication of EP0753062A1 publication Critical patent/EP0753062A1/en
Publication of EP0753062A4 publication Critical patent/EP0753062A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention concerns an oligonucleotide compound, which comprises a ribozyme targeted to the GUA target site at nucleotide 5849 of the HIV-1 SF-2 isolate or a corresponding target site of other HIV-1 isolates. The invention also relates to transfer vectors comprised of RNA or DNA or a combination thereof which on transcription give rise to said compound, to cells comprising a nucleotide sequence which is, or on transcription gives rise to, said compound and to pharmaceutical compositions containing said compound or said transfer vector. <IMAGE>
EP95905220A 1994-01-05 1995-01-05 Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs Withdrawn EP0753062A4 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DK02025406T DK1298208T3 (en) 1994-01-05 1995-01-05 Ribozymes targeting an HIV tat sequence
EP02025406A EP1298208B1 (en) 1994-01-05 1995-01-05 Ribozymes targeting a hiv tat sequence

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US178082 1994-01-05
US08/178,082 US5712384A (en) 1994-01-05 1994-01-05 Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US310259 1994-09-21
US08/310,259 US6114167A (en) 1994-01-05 1994-09-21 Ribozymes targeting the MoMLV PSI packaging sequence and the HIV tat sequence
PCT/IB1995/000050 WO1995018854A1 (en) 1994-01-05 1995-01-05 Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP02025406A Division EP1298208B1 (en) 1994-01-05 1995-01-05 Ribozymes targeting a hiv tat sequence

Publications (2)

Publication Number Publication Date
EP0753062A1 EP0753062A1 (en) 1997-01-15
EP0753062A4 true EP0753062A4 (en) 1999-10-20

Family

ID=26873946

Family Applications (2)

Application Number Title Priority Date Filing Date
EP95905220A Withdrawn EP0753062A4 (en) 1994-01-05 1995-01-05 Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
EP02025406A Expired - Lifetime EP1298208B1 (en) 1994-01-05 1995-01-05 Ribozymes targeting a hiv tat sequence

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP02025406A Expired - Lifetime EP1298208B1 (en) 1994-01-05 1995-01-05 Ribozymes targeting a hiv tat sequence

Country Status (14)

Country Link
EP (2) EP0753062A4 (en)
JP (1) JP3691849B2 (en)
CN (1) CN1267552C (en)
AT (1) ATE320487T1 (en)
AU (1) AU698730B2 (en)
CA (1) CA2180358A1 (en)
DE (1) DE69534864T2 (en)
DK (1) DK1298208T3 (en)
ES (1) ES2260376T3 (en)
IL (1) IL112261A (en)
NO (1) NO319376B1 (en)
NZ (1) NZ278432A (en)
PT (1) PT1298208E (en)
WO (1) WO1995018854A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
WO1997007808A1 (en) * 1995-08-25 1997-03-06 The Regents Of The University Of California Chimeric antiviral agents which incorporate rev binding nucleic acids
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
JP2000503527A (en) * 1995-11-28 2000-03-28 ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン Conditionally replicating viral vectors and their uses
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
ES2374534T3 (en) 1998-03-20 2012-02-17 Commonwealth Scientific And Industrial Research Organisation GENES EXPRESSION CONTROL.
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1229134A3 (en) 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
ATE490322T1 (en) 2001-07-10 2010-12-15 Johnson & Johnson Res Pty Ltd METHOD FOR GENETIC MODIFICATION OF HEMATOPOETIC PROGENIC CELLS AND USES OF THE MODIFIED CELLS
ES2358187T3 (en) 2001-07-10 2011-05-06 JOHNSON &amp; JOHNSON RESEARCH PTY LIMITED PROCEDURES FOR THE GENETIC MODIFICATION OF HEMATOPOYETIC PROGENITING CELLS AND USES OF THE MODIFIED CELLS.
CN102841007A (en) * 2012-09-05 2012-12-26 福建省农业科学院畜牧兽医研究所 Semen diluent convenient to count duck sperms and application method thereof
CN113549641B (en) * 2021-06-29 2023-12-22 复旦大学 Ribozyme-mediated polycistronic vector and construction method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004324A1 (en) * 1989-09-25 1991-04-04 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
WO1994016736A1 (en) * 1993-01-22 1994-08-04 University Research Corporation Localization of therapeutic agents
EP0612844A2 (en) * 1993-02-25 1994-08-31 Ortho Pharmaceutical Corporation Expression constructs containing HIV inhibitory antisense and other nucleotide sequences, retroviral vectors and recombinant retroviruses containing same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0578776A4 (en) * 1991-04-05 1995-04-12 Edison Animal Biotech Center INHIBITION OF RETROVIRUS MEANS OF PACKING SEQUENCES OF COMPLEMENTARY ANTISENSE NUCLEIC ACIDS.
WO1995004818A1 (en) * 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004324A1 (en) * 1989-09-25 1991-04-04 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
WO1994016736A1 (en) * 1993-01-22 1994-08-04 University Research Corporation Localization of therapeutic agents
EP0612844A2 (en) * 1993-02-25 1994-08-31 Ortho Pharmaceutical Corporation Expression constructs containing HIV inhibitory antisense and other nucleotide sequences, retroviral vectors and recombinant retroviruses containing same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHEN, C.-J. ET AL.: "Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication - potential effectiveness against most presently sequenced HIV-1 isolates", NUCLEIC ACIDS RESEARCH., vol. 20, 11 September 1992 (1992-09-11), pages 4581 - 4589, XP002111362, ISSN: 0305-1048 *
HAN, L. ET AL.: "Inhibition of moloney murine leukemia virus-induced leukemia in transgenic mice expressing antisense RNA complementary to the retroviral packaging sequences", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 88, May 1991 (1991-05-01), pages 4313 - 4317, XP002111360, ISSN: 0027-8424 *
LO, S. ET AL.: "Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA", VIROLOGY., vol. 190, 1992, pages 176 - 183, XP002111361, ISSN: 0042-6822 *
ROSSI J J ET AL: "RIBOZYMES AS ANTI-HIV-1 THERAPEUTIC AGENTS: PRINCIPLES, APPLICATIONS, AND PROBLEMS", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 8, no. 2, 1 February 1992 (1992-02-01), pages 183 - 189, XP002026934, ISSN: 0889-2229 *
YU M ET AL: "PROGRESS TOWARDS GENE THERAPY FOR HIV INFECTION", GENE THERAPY, vol. 1, no. 1, January 1994 (1994-01-01), pages 13 - 26, XP002050715, ISSN: 0969-7128 *

Also Published As

Publication number Publication date
IL112261A (en) 2005-08-31
JP3691849B2 (en) 2005-09-07
DK1298208T3 (en) 2006-07-24
EP1298208A3 (en) 2004-01-07
AU1391295A (en) 1995-08-01
AU698730B2 (en) 1998-11-05
NO962826L (en) 1996-08-27
ES2260376T3 (en) 2006-11-01
WO1995018854A1 (en) 1995-07-13
EP1298208B1 (en) 2006-03-15
EP1298208A2 (en) 2003-04-02
ATE320487T1 (en) 2006-04-15
CN1267552C (en) 2006-08-02
JPH09508004A (en) 1997-08-19
EP0753062A1 (en) 1997-01-15
IL112261A0 (en) 1995-03-30
DE69534864T2 (en) 2007-02-22
DE69534864D1 (en) 2006-05-11
NO962826D0 (en) 1996-07-04
CN1145638A (en) 1997-03-19
CA2180358A1 (en) 1995-07-13
NO319376B1 (en) 2005-07-25
PT1298208E (en) 2006-10-31
NZ278432A (en) 1998-06-26

Similar Documents

Publication Publication Date Title
IL112261A0 (en) Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
KR960703170A (en) ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTIC USE THEREOF IN HUMAN IMMUNODEFICIENCY VIRUS INFECTION
AU6871398A (en) Method for enhancing expression of a foreign or endogenous gene product in pla nts
WO1996019568A3 (en) Stabilized ribozyme analogs
CY1106513T1 (en) TRIPLE LENTINOIC DNA AND VEHICLES AND RECOMBINANT CELLS CONTAINING TRIPLE LENTINOIC DNA
HUP0204199A2 (en) Transport vectors
FI946201A (en) Self-stabilized oligonucleotides as therapeutic agents
CA2418442A1 (en) Novel helper functions for recombinant vector production
CA2340416A1 (en) Co-lyophilized complex of a nucleic acid vector and a formulating agent
EP1017797A4 (en) NON-ORIGINATING PRIMATE LENTIVIRUS VECTORS AND PACKAGING SYSTEMS
AU692163B2 (en) Retroviral vector for the transfer and expression of genes for therapeutical purposes in eucaryotic cells
DE69528362D1 (en) OLIGOMER PHOSPHORAMIDATE AND PHOSPHORTHIOAMIDATE COMPOUNDS
WO1999029871A3 (en) Circovirus sequences related to piglet weight loss disease (pwd)
WO1999041402A3 (en) Targeting of genetic vaccine vectors
WO1998056937A3 (en) Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus
WO1998039463A3 (en) Lentivirus based vector and vector system
IL133544A0 (en) Lag-3 splice variants, their preparation and use
IL122206A0 (en) Adeno-associated virus vectors for gene expression
DK0630409T3 (en) Defect-packing non-oncovirus vectors based on MPMV
IL117194A0 (en) Amplifying sequences vectors comprising them and their uses in compositions for the expression of nucleotide sequences and pharmaceutical compositions containing them
BR9407693A (en) Nucleotide sequence vector pharmaceutical composition use of the vector and a compound
WO1999028439A3 (en) Erythrovirus and its applications
NO995858L (en) New class of cationic nucleic acid transfer agents
CA2167630A1 (en) cDNA of DOCK180 Gene and DOCK180 Protein
WO2004003209A3 (en) Nucleic acid isolated from the 5&#39; non translated region (5&#39;ntr) end of the human fgf-1 gene having ires activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960731

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENE SHEARS PTY LIMITED

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENE SHEARS PTY LIMITED

A4 Supplementary search report drawn up and despatched

Effective date: 19990903

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020305

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20021119